Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-05-24
2002-04-23
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S006400
Reexamination Certificate
active
06376469
ABSTRACT:
TECHNICAL FIELD
The present invention relates to a crystalline form of amrubicin hydrochloride which is useful as a drug.
BACKGROUND OF THE INVENTION
Japanese Patent KOKOKU(Examined) 3-5397 and U.S. Pat. No. 4,673,668 disclose the preparation of (7S,9S)-9-acetyl-9-amino-7-[(2-deoxy-&bgr;-D-erythro-pentapyranosyl)oxy]-7,8,9, 10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride and its usage as a cancer-chemotherapeutical agent, which is referred to as “amrubicin hydrochloride” hereinafter and is represented by the formula:
However, these Patents do not specifically disclose thermally stable crystalline amrubicin hydrochloride.
Japanese Patent 2,603,480 and U. S. Pat. No. 4,952,566 disclose stable preparations of amrubicin hydrochloride containing agents such as L-cysteine. These patents disclose preparations for stabilized injection, but do not disclose the stabilization of amrubicin hydrochloride itself as a medicine or a bulk drug.
DISCLOSURE OF THE INVENTION
The inventors of the present invention have intensively carried out research on the crystalline forms of amrubicin hydrochloride, and found that a specific crystal form of amrubicin hydrochloride which is referred to as “&bgr;-type crystalline amrubicin hydrochloride” hereinafter, has excellent thermal stability. Thus, the present invention has been accomplished.
Accordingly, the objects of the present invention are as follows:
[1] A crystalline amrubicin hydrochloride having a powder X-ray diffraction pattern as given in Table 1
TABLE 1
diffraction angle(2&thgr;)
relative intensity(%)
(average value)
(average value)
6.3
100
6.7
56
10.1
44
15.3
36
20.3
56
25.6
37
26.5
61
26.9
52
[2] A process of preparing a crystalline amrubicin hydrochloride according to [1] comprising crystallizing amrubicin hydrochloride at a temperature of 15° C. or above.
[3] A process according to [2] comprising crystallizing amrubicin hydrochloride from a mixture of (a) hydrophilic organic solvent and (b) a solution of amrubicin hydrochloride in water or a mixture of water and hydrophilic organic solvent, at a temperature of 15° C. or above.
[4] A process according to [2] comprising:
(1) dissolving amrubicin hydrochloride in water or a mixture of water and hydrophilic organic solvent;
(2) adjusting the pH of the solution to a value of from pH 1.5 to pH 4;
(3) crystallizing amrubicin hydrochloride by adding the solution to hydrophilic organic solvent at a temperature of 15° C. or above, preferably up to 50° C.
[5] A process according to [2], [3] or [4], wherein the crystallization temperature is 22° C. to 40° C.
[6] A process according to [3], [4] or [5], wherein the hydrophilic organic solvent (a) is acetone, isopropanol or acetonitrile.
[7] A process of preparing a freeze-dried preparation of amrubicin hydrochloride, comprising dissolving crystalline amrubicin hydrochloride according to [1] in water, and freeze-drying the dissolved amrubicin hydrochloride.
[8] A process according to [7] comprising:
(1) dissolving crystalline amrubicin hydrochloride according to [1] and L-cysteine or a salt thereof in water;
(2) adjusting the pH of the solution to a value of from pH 2 to pH 5; and
(3) freeze-drying the dissolved amrubicin hydrochloride.
[9] Use of crystalline amrubicin hydrochloride according to [1] in the production of a freeze-dried pharmaceutical formulation.
[10] A crystalline amrubicin hydrochloride according to [1] for use in the treatment of the human or animal body by therapy.
[11] Use of a crystalline amrubicin hydrochloride according to [1] in the preparation of a medicament comprising a freeze-dried form thereof for use in the treatment of cancer by injection of said freeze-dried form into a patient in need of such treatment.
[12] A pharmaceutical composition comprising a crystalline amrubicin hydrochloride according to [1] and a pharmaceutically acceptable carrier.
[13] A method of treating cancer comprising administrating to a person in need thereof, a freeze-dried preparation of amrubicin hydrochloride prepared according to [7] or [8].
[14] A method of treating cancer comprising administrating to a person in need thereof, a pharmaceutical composition according to [12].
REFERENCES:
patent: 4673668 (1987-06-01), Ishizumi et al.
patent: 4952566 (1990-08-01), Sakamaki et al.
patent: 6184365 (2001-02-01), Takeuchi et al.
patent: 6187758 (2001-02-01), Portello et al.
patent: A107486 (1984-05-01), None
patent: A302729 (1989-02-01), None
Kikuo Ishizumi et al., J. Org. Chem., 1987, 52, pp. 4477-4485, Stereospecific Total Synthesis of 9-Aminoanthracyclines: . . . .
Shimago Kozo
Uenishi Yuko
Birch & Stewart Kolasch & Birch, LLP
Lambkin Deborah C.
Sumitomo Pharmaceuticals Company Limited
LandOfFree
Crystalline amrubicin hydrochloride does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline amrubicin hydrochloride, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline amrubicin hydrochloride will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2900079